Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry

Alessandro Pastore(Memorial Sloan Kettering Cancer Center), Oliver Weigert(German Cancer Research Center), Donna Neuberg(Otsuka (Japan)), Paul Van Hummelen, Monika Szczepanowski(Christian-Albrechts-Universität zu Kiel), Christoffer Hother(BC Cancer Agency), Matthew D. Ducar(Brigham and Women's Hospital), Joseph M. Connors, Laurie H. Sehn(BC Cancer Agency), David M. Weinstock(Broad Institute), Andreas Rosenwald(Comprehensive Cancer Center Mainfranken), Annette M. Staiger(Robert Bosch Hospital), Randy D. Gascoyne(BC Cancer Agency), Eva Hoster(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Mark A. Murakami(Harvard University), Robert Kridel(University of Toronto), Martin Dreyling(LMU Klinikum), Nadja Kopp(Dana-Farber Cancer Institute), Daisuke Ennishi(BC Cancer Agency), Ashwini Sunkavalli(Dana-Farber Cancer Institute), Vindi Jurinović(Ludwig-Maximilians-Universität München), Alden A. Moccia(BC Cancer Agency), German Ott(Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology), Ellen Leich(University of Würzburg), Harald Stein(Franklin University), Anja Mottok(Comprehensive Cancer Center Mainfranken), Hennady P. Shulha(BC Cancer Agency), Peter Mӧller(University Hospital Ulm), Wolfgang Hiddemann(Christian-Albrechts-Universität zu Kiel), Martin L. Hansmann(Goethe University Frankfurt), Michael Unterhalt, Alfred C. Feller, Heike Horn(Robert Bosch Hospital), Christiane Pott(University Hospital Schleswig-Holstein)

The Lancet Oncology

August 7, 2015

Cited by 613

|Nature|2000|9.9k

|New England Journal of Medicine|2002|3.9k

|New England Journal of Medicine|2018|2.3k

|Cancer Discovery|2017|2k

|New England Journal of Medicine|2008|1.8k

Related Papers